< Back to previous page
Researcher
Johan Vansteenkiste
- Disciplines:Respiratory medicine
Affiliations
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) (Division)
Member
From1 Oct 1999 → 30 Sep 2022
Projects
1 - 3 of 3
- Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approachFrom5 Oct 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade in non-small cell lung cancer.From1 Aug 2019 → 1 Aug 2023Funding: FWO Strategic Basic Research Grant, Foundations, funds and other with scientific goal
- Unraveling the common genetic basis for COPD, emphysema and lung cancer.From1 Aug 2010 → 16 Dec 2015Funding: Private funding of national origin - undefined, FWO fellowships
Publications
31 - 40 of 278
- Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC(2020)
Authors: Johan Vansteenkiste
Pages: 1472 - 1483 - Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial(2020)
Authors: C Faivre-Finn, D Vicente, T Kurata, D Planchard, L Paz-Ares, Johan Vansteenkiste, DR Spigel, MC Garassino, M Reck, S Senan, et al.
Pages: S1178 - S1179 - IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy(2020)
Authors: Johan Vansteenkiste
Pages: 709 - 740 - A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma(2020)
Authors: Johan Vansteenkiste
Pages: 457 - 467 - The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History(2020)
Authors: Johan Vansteenkiste
Pages: 1221 - 1228 - A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer(2020)
Authors: Johan Vansteenkiste
Pages: 1725 - 1735 - An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates (vol 37, pg 21.e1, 2020)(2020)
Authors: Jermaine Goveia, Katerina Rohlenova, Federico Taverna, Lucas Treps, Lena-Christin Conradi, Andreas Pircher, Vincent Geldhof, Laura PMH de Rooij, Joanna Kalucka, Liliana Sokol, et al.
Pages: 421 - 421 - Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study(2020)
Authors: Johan Vansteenkiste
Pages: 392 - 403 - Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS(2020)
Authors: Johan Vansteenkiste
Pages: 191 - 201 - Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC(2020)
Authors: Johan Vansteenkiste
Pages: 288 - 293